Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future

Ophthalmology

Volumn 124, Issue 12, 2017, Pages 1753-1763

  Colijn, Johanna M ^a,u   Buitendijk, Gabriëlle H S ^a   Prokofyeva, Elena ^b,c,u   Alves, Dalila ^f   Cachulo, Maria L ^d,e,f   Khawaja, Anthony P ^g,h,u   Cougnard Gregoire, Audrey ⁱ   Merle, Bénédicte M J ^i,u   Korb, Christina ^j   Erke, Maja G ^l   Bron, Alain ^m,u   Anastasopoulos, Eleftherios ⁿ   Meester Smoor, Magda A ^a   Segato, Tatiana ^q,u   Piermarocchi, Stefano ^q,u   de Jong, Paulus T V M ^a,r   Vingerling, Johannes R ^a   Topouzis, Fotis ^n,u   Creuzot Garcher, Catherine ^m,u   Bertelsen, Geir ^k,u   Pfeiffer, Norbert ^j   Fletcher, Astrid E ^s   Foster, Paul J ^h,o   Silva, Rufino ^d,e,f,u   Korobelnik, Jean François ^i,p,u   Delcourt, Cécile ^i,u   Klaver, Caroline C W ^a,t,u   Ajana, Soufiane ^u   Arango Gonzalez, Blanca ^u   Arndt, Verena ^u   Bhatia, Vaibhav ^u   Bhattacharya, Shomi S ^u   Biarnés, Marc ^u   Borrell, Anna ^u   Bühren, Sebastian ^u   Calado, Sofia M ^u   Cougnard Grégoire, Audrey ^u   Dammeier, Sascha ^u   de Jong, Eiko K ^u   De la Cerda, Berta ^u   den Hollander, Anneke I ^u   Diaz Corrales, Francisco J ^u   Diether, Sigrid ^u   Emri, Eszter ^u   Endermann, Tanja ^u   Ferraro, Lucia L ^u   Garcia, Míriam ^u   Heesterbeek, Thomas J ^u   Honisch, Sabina ^u   Hoyng, Carel B ^u   Kersten, Eveline ^u   Kilger, Ellen ^u   Langen, Hanno ^u   Lengyel, Imre ^u   Luthert, Phil ^u   Maugeais, Cyrille ^u   Meester Smoor, Magda ^u   Monés, Jordi ^u   Nogoceke, Everson ^u   Peto, Tunde ^u   Pool, Frances M ^u   Rodríguez, Eduardo ^u   Ueffing, Marius ^u   Ulrich Bartz Schmidt, Karl U ^u   van Leeuwen, Elisabeth M ^u   Verzijden, Timo ^u   Zumbansen, Markus ^u   Acar, Niyazi ^u   Anastosopoulos, Eleftherios ^u   Azuara Blanco, Augusto ^u   Bergen, Arthur ^u   Binquet, Christine ^u   Bird, Alan ^u   Brétillon, Lionel ^u   Buitendijk, Gabrielle ^u   Cachulo, Maria Luz ^u   Chakravarthy, Usha ^u   Chan, Michelle ^u   Chang, Petrus ^u   Colijn, Johanna ^u   Cumberland, Philippa ^u   Cunha Vaz, José ^u   Daien, Vincent ^u   Deak, Gabor ^u   Delyfer, Marie Noëlle ^u   den Hollander, Anneke ^u   Dietzel, Martha ^u   Erke, Maja Gran ^u   Fauser, Sascha ^u   Finger, Robert ^u   Fletcher, Astrid ^u   Foster, Paul ^u   Founti, Panayiota ^u   Göbel, Arno ^u   Gorgels, Theo ^u   Grauslund, Jakob ^u   Grus, Franz ^u   Hammond, Christopher ^u   Helmer, Catherine ^u   Hense, Hans Werner ^u   Hermann, Manuel ^u   Hoehn, René ^u   Hogg, Ruth ^u   Holz, Frank ^u   Jansonius, Nomdo ^u   Janssen, Sarah ^u   Lamparter, Julia ^u   Le Goff, Mélanie ^u   Leal, Sergio ^u   Lechanteur, Yara ^u   Lehtimäki, Terho ^u   Lotery, Andrew ^u   Leung, Irene ^u   Mauschitz, Matthias ^u   Merle, Bénédicte ^u   Meyer zu Westrup, Verena ^u   Midena, Edoardo ^u   Miotto, Stefania ^u   Mirshahi, Alireza ^u   Mohan Saïd, Sadek ^u   Mueller, Michael ^u   Muldrew, Alyson ^u   Nunes, Sandrina ^u   Oexle, Konrad ^u   Rahi, Jugnoo ^u   Raitakari, Olli ^u   Ribeiro, Luisa ^u   Rougier, Marie Bénédicte ^u   Sahel, José ^u   Salonikiou, Aggeliki ^u   Sanchez, Clarisa ^u   Schmitz Valckenberg, Steffen ^u   Schweitzer, Cédric ^u   Shehata, Jasmin ^u   Silvestri, Giuliana ^u   Simader, Christian ^u   Souied, Eric ^u   Springelkamp, Henriet ^u   Tapp, Robyn ^u   Verhoeven, Virginie ^u   Von Hanno, Therese ^u   Vujosevic, Stela ^u   Williams, Katie ^u   Wolfram, Christian ^u   Yip, Jennifer ^u   Zerbib, Jennyfer ^u   Zwiener, Isabella ^u   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^c Federal Agency for Medicines and Health Products Belgium   (Belgium)

^d UNIVERSITY OF COIMBRA   (Portugal)

^e CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^f ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE AIBILI   (Portugal)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h MOORFIELDS EYE HOSPITAL   (United Kingdom)

ⁱ INSERM U657   (France)

^j UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^k UNIVERSITY OF TROMSØ   (Norway)

^l OSLO UNIVERSITY HOSPITAL   (Norway)

^m DIJON UNIVERSITY HOSPITAL   (France)

ⁿ ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^o UNIVERSITY COLLEGE LONDON   (United Kingdom)

^p BORDEAUX UNIVERSITY HOSPITAL   (France)

^q UNIVERSITY OF PADOVA   (Italy)

^r ACADEMIC MEDICAL CENTER   (Netherlands)

^s LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^t RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^u NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN ANTIBODY;

AGE RELATED MACULAR DEGENERATION; ARTICLE; BEST CORRECTED VISUAL ACUITY; EUROPE; EYE PHOTOGRAPHY; GEOGRAPHIC ATROPHY; GEOGRAPHIC DISTRIBUTION; GROUPS BY AGE; HUMAN; LIFESTYLE; META ANALYSIS; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; SUBRETINAL NEOVASCULARIZATION; VISUAL IMPAIRMENT; AGE DISTRIBUTION; AGED; CAUCASIAN; FEMALE; FORECASTING; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; SEX RATIO; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; VISUAL ACUITY; WET MACULAR DEGENERATION;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FORECASTING; GEOGRAPHIC ATROPHY; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SEX DISTRIBUTION; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 85023611034     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2017.05.035     Document Type: Article

References (53)

1. Bourne, R.R., Jonas, J.B., Flaxman, S.R., et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010. Br J Ophthalmol 98:5 (2014), 629–638.
2. de Jong, P.T., Age-related macular degeneration. N Engl J Med 355:14 (2006), 1474–1485.
3. Ozaki, E., Campbell, M., Kiang, A.S., et al. Inflammation in age-related macular degeneration. Adv Exp Med Biol 801 (2014), 229–235.
4. Wong, W.L., Su, X., Li, X., et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:2 (2014), e106–e116.
5. Lindekleiv, H., Erke, M.G., Projected prevalence of age-related macular degeneration in Scandinavia 2012-2040. Acta Ophthalmol 91:4 (2013), 307–311.
6. Bauer, P., Barthelmes, D., Kurz, M., et al. The potential effect of population development, smoking and antioxidant supplementation on the future epidemiology of age-related macular degeneration in Switzerland. Klin Monbl Augenheilkd 225:5 (2008), 376–379.
7. Friedman, D.S., O'Colmain, B.J., Munoz, B., et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122:4 (2004), 564–572.
8. Rein, D.B., Wittenborn, J.S., Zhang, X., et al. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol 127:4 (2009), 533–540.
9. Owen, C.G., Jarrar, Z., Wormald, R., et al. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol 96:5 (2012), 752–756.
10. Klaver, C.C., Wolfs, R.C., Vingerling, J.R., et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 116:5 (1998), 653–658.
11. Korb, C.A., Kottler, U.B., Wolfram, C., et al. Prevalence of age-related macular degeneration in a large European cohort: results from the population-based Gutenberg Health Study. Graefes Arch Clin Exp Ophthalmol 252:9 (2014), 1403–1411.
12. Hoeg, T.B., Ellervik, C., Buch, H., et al. Danish Rural Eye Study: epidemiology of adult visual impairment. Ophthalmic Epidemiol 23:1 (2016), 53–62.
13. Prokofyeva, E., Zrenner, E., Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Res 47:4 (2012), 171–188.
14. Claessen, H., Genz, J., Bertram, B., et al. Evidence for a considerable decrease in total and cause-specific incidences of blindness in Germany. Eur J Epidemiol 27:7 (2012), 519–524.
15. Skaat, A., Chetrit, A., Belkin, M., et al. Time trends in the incidence and causes of blindness in Israel. Am J Ophthalmol 153:2 (2012), 214–221.e1.
16. Delcourt, C., Korobelnik, J.F., Buitendijk, G.H., et al. Ophthalmic epidemiology in Europe: the “European Eye Epidemiology” (E3) consortium. Eur J Epidemiol 31:2 (2016), 197–210.
17. Gragoudas, E.S., Adamis, A.P., Cunningham, E.T. Jr., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:27 (2004), 2805–2816.
18. Wolf, S., Current status of anti-vascular endothelial growth factor therapy in Europe. Jpn J Ophthalmol 52:6 (2008), 433–439.
19. Cachulo Mda, L., Lains, I., Lobo, C., et al. Age-related macular degeneration in Portugal: prevalence and risk factors in a coastal and an inland town. The Coimbra Eye Study - Report 2. Acta Ophthalmol 94:6 (2016), e442–e453.
20. Cachulo Mda, L., Lobo, C., Figueira, J., et al. Prevalence of Age-Related Macular Degeneration in Portugal: The Coimbra Eye Study - Report 1. Ophthalmologica 233:3–4 (2015), 119–127.
21. van Leeuwen, R., Chakravarthy, U., Vingerling, J.R., et al. Grading of age-related maculopathy for epidemiological studies: is digital imaging as good as 35-mm film?. Ophthalmology 110:8 (2003), 1540–1544.
22. Eurostatv3.1.15-20160425-5608-PROD_EUROBASE. http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=proj_15npms&lang=en Accessed February 8, 2016.
23. Haldane, J.B., The estimation and significance of the logarithm of a ratio of frequencies. Ann Hum Genet 20:4 (1956), 309–311.
24. Division UNSComposition of macro geographical (continental) regions, geographical sub-regions, and selected economic and other groupings. Available at: https://unstats.un.org/unsd/methodology/m49; Accessed March 18, 2015.
25. Klein, R., Chou, C.F., Klein, B.E., et al. Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol 129:1 (2011), 75–80.
26. Borger, P.H., van Leeuwen, R., Hulsman, C.A., et al. Is there a direct association between age-related eye diseases and mortality? The Rotterdam Study. Ophthalmology 110:7 (2003), 1292–1296.
27. Wang, J., Xue, Y., Thapa, S., et al. Relation between age-related macular degeneration and cardiovascular events and mortality: a systematic review and meta-analysis. Biomed Res Int, 2016, 2016, 8212063.
28. McGuinness, M.B., Karahalios, A., Kasza, J., et al. Survival bias when assessing risk factors for age-related macular degeneration: a tutorial with application to the exposure of smoking. Ophthalmic Epidemiol, 2017, 1–10.
29. Klein, R., Knudtson, M.D., Lee, K.E., et al. Age-period-cohort effect on the incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 115:9 (2008), 1460–1467.
30. Crimmins, E.M., Hayward, M.D., Hagedorn, A., et al. Change in disability-free life expectancy for Americans 70-years-old and older. Demography 46:3 (2009), 627–646.
31. Koch, M.B., Davidsen, M., Andersen, L.V., et al. Increasing prevalence despite decreasing incidence of ischaemic heart disease and myocardial infarction. A national register based perspective in Denmark, 1980-2009. Eur J Prev Cardiol 22:2 (2015), 189–195.
32. Davies, A.R., Smeeth, L., Grundy, E.M., Contribution of changes in incidence and mortality to trends in the prevalence of coronary heart disease in the UK: 1996 2005. Eur Heart J 28:17 (2007), 2142–2147.
33. Satizabal, C.L., Beiser, A.S., Chouraki, V., et al. Incidence of dementia over three decades in the Framingham Heart Study. N Engl J Med 374:6 (2016), 523–532.
34. Plessz, M., Gueguen, A., Goldberg, M., et al. Ageing, retirement and changes in vegetable consumption in France: findings from the prospective GAZEL cohort. Br J Nutr 114:6 (2015), 979–987.
35. Pot, G.K., Prynne, C.J., Almoosawi, S., et al. Trends in food consumption over 30 years: evidence from a British birth cohort. Eur J Clin Nutr 69:7 (2015), 817–823.
36. Jungjohann, S.M., Luhrmann, P.M., Bender, R., et al. Eight-year trends in food, energy and macronutrient intake in a sample of elderly German subjects. Br J Nutr 93:3 (2005), 361–378.
37. OECD (2013), Change in smoking rates: Percentage change over the period 1990-2010 or latest available period, in OECD Factbook 2013, OECD Publishing, Paris. DOI: http://dx.doi.org/10.1787/factbook-2013-graph252-en.
38. Huang, G.H., Klein, R., Klein, B.E., Tomany, S.C., Birth cohort effect on prevalence of age-related maculopathy in the Beaver Dam Eye Study. Am J Epidemiol 157:8 (2003), 721–729.
39. Mitchell, P., Smith, W., Attebo, K., Wang, J.J., Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 102:10 (1995), 1450–1460.
40. Erke, M.G., Bertelsen, G., Peto, T., et al. Prevalence of age-related macular degeneration in elderly Caucasians: the Tromso Eye Study. Ophthalmology 119:9 (2012), 1737–1743.
41. Augood, C.A., Vingerling, J.R., de Jong, P.T., et al. Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol 124:4 (2006), 529–535.
42. Jonasson, F., Arnarsson, A., Sasaki, H., et al. The prevalence of age-related maculopathy in Iceland: Reykjavik eye study. Arch Ophthalmol 121:3 (2003), 379–385.
43. Bjornsson, O.M., Syrdalen, P., Bird, A.C., et al. The prevalence of age-related maculopathy (ARM) in an urban Norwegian population: the Oslo Macular study. Acta Ophthalmol Scand 84:5 (2006), 636–641.
44. Group, C.R., Martin, D.F., Maguire, M.G., et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:20 (2011), 1897–1908.
45. Boyer, D.S., Heier, J.S., Brown, D.M., et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 116:9 (2009), 1731–1739.
46. Bloch, S.B., Larsen, M., Munch, I.C., Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 153:2 (2012), 209–213.e2.
47. Granstam, E., Westborg, I., Barkander, A., et al. Reduced occurrence of severe visual impairment after introduction of anti-Vascular Endothelial Growth Factor in wet age-related macular degeneration - a population- and register-based study from northern Sweden. Acta Ophthalmol 94:7 (2016), 646–651.
48. Heraghty, J., Cummins, R., A layered approach to raising public awareness of macular degeneration in Australia. Am J Public Health 102:9 (2012), 1655–1659.
49. Bertram, B., Gante, C., Hilgers, R.D., Increase in examinations for cataracts, glaucoma, diabetic retinopathy and age-related macular degeneration: Comparative cross-sectional study between 2010 and 1997 in ophthalmological practices. [in German]. Ophthalmologe 111:8 (2014), 757–764.
50. Marques, A.P., Macedo, A.F., Perelman, J., et al. Diffusion of anti-VEGF injections in the Portuguese National Health System. BMJ Open, 5(11), 2015, e009006.
51. Keenan, T.D., Wotton, C.J., Goldacre, M.J., Trends over time and geographical variation in rates of intravitreal injections in England. Br J Ophthalmol 96:3 (2012), 413–418.
52. Yehoshua, Z., Gregori, G., Sadda, S.R., et al. Comparison of drusen area detected by spectral domain optical coherence tomography and color fundus imaging. Invest Ophthalmol Vis Sci 54:4 (2013), 2429–2434.
53. Wang, Y.T., Tadarati, M., Wolfson, Y., et al. Comparison of prevalence of diabetic macular edema based on monocular fundus photography vs optical coherence tomography. JAMA Ophthalmol 134:2 (2016), 222–228.